Inhibition of PI3K/Akt/mTOR Signaling Pathway Enhances the Sensitivity of the SKOV3/DDP Ovarian Cancer Cell Line to Cisplatin in Vitro

Overview

Journal Chin J Cancer Res

Specialty Oncology

Date 2014 Nov 18

PMID 25400422

Citations 25

Authors

Yunlang Cai

Xiaoqiang Tan

Jun Liu

Yang Shen

Di Wu

Mulan Ren

Peilin Huang

Dandan Yu

Affiliations

Soon will be listed here.

Abstract

The activation of the PI3K/AKT/mTOR pathway plays a key role in ovarian cancer tumorigenesis, progression and chemotherapy resistance. This study aimed to explore the possible mechanism that PI-103, a dual inhibitor of phosphatidylinositide 3-kinase and mTOR, enhances the sensitivity of SKOV3/DDP ovarian cancer cell line to cisplatin chemotherapy. The results showed that PI-103 could significantly increase the sensitivity of SKVO3/DDP cells to cisplatin through inhibiting the activation of PI3K/Akt/mTOR signaling pathway and inducing cell cycle arrest and apoptosis.

Citing Articles

Combination of Cannabidiol with Cisplatin or Paclitaxel Analysis Using the Chou-Talalay Method and Chemo-Sensitization Evaluation in Platinum-Resistant Ovarian Cancer Cells.

Ismail J, Shebaby W, Azar Atallah S, Taleb R, Kawrani S, Faour W Biomedicines. 2025; 13(2).

PMID: 40002932 PMC: 11852490. DOI: 10.3390/biomedicines13020520.

MAD2L2, a key regulator in ovarian cancer and promoting tumor progression.

Xu K, Zheng X, Shi H, Ou J, Ding H Sci Rep. 2024; 14(1):130.

PMID: 38167649 PMC: 10761867. DOI: 10.1038/s41598-023-50744-7.

DKK1 Promotes Epithelial-Mesenchymal Transition and Cisplatin Resistance in Gastric Cancer via Activation of the PI3K/AKT Pathway.

Li J, Zhang Y, Ye F, Qian P, Qin Z, Li D Cancers (Basel). 2023; 15(19).

PMID: 37835450 PMC: 10571993. DOI: 10.3390/cancers15194756.

PI3K/AKT signaling pathway as a critical regulator of Cisplatin response in tumor cells.

Navaei Z, Khalili-Tanha G, Zangouei A, Abbaszadegan M, Moghbeli M Oncol Res. 2023; 29(4):235-250.

PMID: 37303943 PMC: 10208004. DOI: 10.32604/or.2022.025323.

Comprehensive analysis of the glutathione S-transferase Mu (GSTM) gene family in ovarian cancer identifies prognostic and expression significance.

Zhang J, Li Y, Zou J, Lai C, Zeng T, Peng J Front Oncol. 2022; 12:968547.

PMID: 35965498 PMC: 9366399. DOI: 10.3389/fonc.2022.968547.

References

Dobbin Z, Landen C . The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer. Int J Mol Sci. 2013; 14(4):8213-27. PMC: 3645739. DOI: 10.3390/ijms14048213. View

Haluska F, Tsao H, Wu H, Haluska F, Lazar A, Goel V . Genetic alterations in signaling pathways in melanoma. Clin Cancer Res. 2006; 12(7 Pt 2):2301s-2307s. DOI: 10.1158/1078-0432.CCR-05-2518. View

Bender A, Opel D, Naumann I, Kappler R, Friedman L, von Schweinitz D . PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis. Oncogene. 2010; 30(4):494-503. DOI: 10.1038/onc.2010.429. View

Cavazzoni A, Bonelli M, Fumarola C, La Monica S, Airoud K, Bertoni R . Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. Cancer Lett. 2012; 323(1):77-87. DOI: 10.1016/j.canlet.2012.03.034. View

Morgensztern D, McLeod H . PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs. 2005; 16(8):797-803. DOI: 10.1097/01.cad.0000173476.67239.3b. View

Lee S, Choi E, Jin C, Kim D . Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol. 2005; 97(1):26-34. DOI: 10.1016/j.ygyno.2004.11.051. View

Peng D, Wang J, Zhou J, Wu G . Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells. Biochem Biophys Res Commun. 2010; 394(3):600-5. PMC: 4063277. DOI: 10.1016/j.bbrc.2010.03.029. View

Janmaat M, Kruyt F, Rodriguez J, Giaccone G . Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase.... Clin Cancer Res. 2003; 9(6):2316-26. View

Chen J, Zhou L, Entin-Meer M, Yang X, Donker M, Knight Z . Characterization of structurally distinct, isoform-selective phosphoinositide 3'-kinase inhibitors in combination with radiation in the treatment of glioblastoma. Mol Cancer Ther. 2008; 7(4):841-50. DOI: 10.1158/1535-7163.MCT-07-0393. View

10.

Wartenberg M, Ling F, Muschen M, Klein F, Acker H, Gassmann M . Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. FASEB J. 2003; 17(3):503-5. DOI: 10.1096/fj.02-0358fje. View

11.

Shukla S, Gupta S . Molecular mechanisms for apigenin-induced cell-cycle arrest and apoptosis of hormone refractory human prostate carcinoma DU145 cells. Mol Carcinog. 2004; 39(2):114-26. DOI: 10.1002/mc.10168. View

12.

Perez R, Hamilton T, Ozols R, Young R . Mechanisms and modulation of resistance to chemotherapy in ovarian cancer. Cancer. 1993; 71(4 Suppl):1571-80. DOI: 10.1002/cncr.2820710424. View

13.

Schwab J, Antonescu C, Boland P, Healey J, Rosenberg A, Nielsen P . Combination of PI3K/mTOR inhibition demonstrates efficacy in human chordoma. Anticancer Res. 2009; 29(6):1867-71. View

14.

Mabuchi S, Altomare D, Cheung M, Zhang L, Poulikakos P, Hensley H . RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res. 2007; 13(14):4261-70. DOI: 10.1158/1078-0432.CCR-06-2770. View

15.

Singh R, Agarwal C, Agarwal R . Inositol hexaphosphate inhibits growth, and induces G1 arrest and apoptotic death of prostate carcinoma DU145 cells: modulation of CDKI-CDK-cyclin and pRb-related protein-E2F complexes. Carcinogenesis. 2003; 24(3):555-63. DOI: 10.1093/carcin/24.3.555. View

16.

Mabuchi S, Kawase C, Altomare D, Morishige K, Sawada K, Hayashi M . mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res. 2009; 15(17):5404-13. PMC: 2743856. DOI: 10.1158/1078-0432.CCR-09-0365. View

17.

Omura G, Brady M, Homesley H, YORDAN E, Major F, Buchsbaum H . Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol. 1991; 9(7):1138-50. DOI: 10.1200/JCO.1991.9.7.1138. View

18.

Nicholson K, Anderson N . The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal. 2002; 14(5):381-95. DOI: 10.1016/s0898-6568(01)00271-6. View

19.

Conte P, Cianci C, Gadducci A . Up date in the management of advanced ovarian carcinoma. Crit Rev Oncol Hematol. 1999; 32(1):49-58. DOI: 10.1016/s1040-8428(99)00036-0. View

20.

Cortot A, Armand J, Soria J . [PI3K-AKT-mTOR pathway inhibitors]. Bull Cancer. 2006; 93(1):19-26. View